Protalix BioTherapeutics Inc

Find Ratings Reports
PLX : AMEX : Health Care
$0.502 up 0.017 | 3.5%
Today's Range: 0.4875 - 0.515
Avg. Daily Volume: 2253700.0
01/19/17 - 3:58 PM ET

Financial Analysis


PROTALIX BIOTHERAPEUTICS INC's gross profit margin for the third quarter of its fiscal year 2016 has significantly increased when compared to the same period a year ago. Even though sales increased, the net income has decreased, representing a decrease to the bottom line. PROTALIX BIOTHERAPEUTICS INC is extremely liquid. Currently, the Quick Ratio is 5.17 which clearly shows the ability to cover any short-term cash needs. The company managed to increase its liquidity from the same period a year ago, despite already having strong liquidity to begin with. This would indicate improved cash flow.

At the same time, stockholders' equity ("net worth") has greatly increased by 77.95% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.



Income Statement Q3 FY16 Q3 FY15
Net Sales ($mil)4.671.34
EBITDA ($mil)-6.17-4.41
EBIT ($mil)-6.65-5.0
Net Income ($mil)-7.29-3.82


Balance Sheet Q3 FY16 Q3 FY15
Cash & Equiv. ($mil)51.3234.25
Total Assets ($mil)70.4759.49
Total Debt ($mil)72.4367.77
Equity ($mil)-15.1-68.51


Profitability Q3 FY16 Q3 FY15
Gross Profit Margin19.38-330.39
EBITDA Margin-132.01-330.38
Operating Margin-142.36-374.4
Sales Turnover0.10.1
Return on Assets65.49-39.21
Return on Equity0.00.0
Debt Q3 FY16 Q3 FY15
Current Ratio5.772.1
Debt/Capital1.26-91.96
Interest Expense0.780.78
Interest Coverage-8.57-6.45


Share Data Q3 FY16 Q3 FY15
Shares outstanding (mil)99.9394.15
Div / share0.00.0
EPS-0.07-0.06
Book value / share-0.15-0.73
Institutional Own % n/a n/a
Avg Daily Volume2066198.0114984.0

Valuation


SELL. The current P/E ratio is negative, which has no meaningful value in the assessment of premium or discount valuation, it simply displays that the company has negative earnings. Along with this, the price-to-book ratio is also meaningless due to a negative book value for the company, making any comparisons useless. The price-to-sales ratio is well above the S&P 500 average, but well below the industry average.


Price/Earnings
1 2 3 4 5
premium   discount
  Price/Cash Flow
1 2 3 4 5
premium   discount
PLX NM Peers 34.33   PLX NM Peers 27.22

Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.

PLX's P/E is negative making this valuation measure meaningless.

 

Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.

PLX's P/CF is negative making the measure meaningless.

 
Price/Projected
Earnings
1 2 3 4 5
premium   discount
  Price to
Earnings/Growth
1 2 3 4 5
premium   discount
PLX NM Peers 24.82   PLX NA Peers 0.41

Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.

PLX's ratio is negative making this valuation measure meaningless.

 

Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.

Ratio not available.

 
Price/Book
1 2 3 4 5
premium   discount
  Earnings Growth
1 2 3 4 5
lower   higher
PLX NM Peers 11.43   PLX -25.00 Peers 3.61

Neutral. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.

PLX's P/B is negative making this valuation measure meaningless.

 

Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.

However, PLX is expected to significantly trail its peers on the basis of its earnings growth rate.

 
Price/Sales
1 2 3 4 5
premium   discount
  Sales Growth
1 2 3 4 5
premium   discount
PLX 5.75 Peers 136.62   PLX 23.83 Peers 532.92

Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.

PLX is trading at a significant discount to its industry on this measurement.

 

Lower. A sales growth rate that trails the industry implies that a company is losing market share.

PLX significantly trails its peers on the basis of sales growth

 

 

Latest Stock Upgrades/Downgrades